%0 Journal Article
%A Fuchs, Michael
%A Jacob, Anne Sophie
%A Kaul, Helen
%A Kobe, Carsten
%A Kuhnert, Georg
%A Pabst, Thomas
%A Greil, Richard
%A Bröckelmann, Paul J
%A Topp, Max S
%A Just, Marianne
%A Hertenstein, Bernd
%A Soekler, Martin
%A Vogelhuber, Martin
%A Zijlstra, Josée M
%A Keller, Ulrich Bernd
%A Krause, Stefan W
%A Dührsen, Ulrich
%A Meissner, Julia
%A Viardot, Andreas
%A Eich, Hans-Theodor
%A Baues, Christian
%A Diehl, Volker
%A Rosenwald, Andreas
%A Buehnen, Ina
%A von Tresckow, Bastian
%A Dietlein, Markus
%A Borchmann, Peter
%A Engert, Andreas
%A Eichenauer, Dennis A
%T Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
%J Leukemia
%V 38
%N 1
%@ 0887-6924
%C London
%I Springer Nature
%M DKFZ-2023-02095
%P 160-167
%D 2024
%Z 2024 Jan;38(1):160-167
%X The primary analysis of the GHSG HD16 trial indicated a significant loss of tumor control with PET-guided omission of radiotherapy (RT) in patients with early-stage favorable Hodgkin lymphoma (HL). This analysis reports long-term outcomes. Overall, 1150 patients aged 18-75 years with newly diagnosed early-stage favorable HL were randomized between standard combined-modality treatment (CMT) (2x ABVD followed by PET/CT [PET-2] and 20 Gy involved-field RT) and PET-2-guided treatment omitting RT in case of PET-2 negativity (Deauville score [DS] < 3). The study aimed at excluding inferiority of PET-2-guided treatment and assessing the prognostic impact of PET-2 in patients receiving CMT. At a median follow-up of 64 months, PET-2-negative patients had a 5-year progression-free survival (PFS) of 94.2
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37845285
%R 10.1038/s41375-023-02064-y
%U https://inrepo02.dkfz.de/record/284784